84 results on '"Griffini, S."'
Search Results
2. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
- Author
-
Cugno, M., Gualtierotti, R., Possenti, I., Testa, S., Tel, F., Griffini, S., Grovetti, E., Tedeschi, S., Salardi, S., Cresseri, D., Messa, P., and Ardissino, G.
- Published
- 2014
- Full Text
- View/download PDF
3. Short expressive language evaluation by French teachers during children's fourth year (SELEFT4)
- Author
-
Labrell, F., Dellatolas, G., Griffini, S., and Lalande, C.
- Published
- 2013
- Full Text
- View/download PDF
4. Carotid artery stenting during endovascular thrombectomy for acute ischemic stroke with tandem occlusion: the Italian Registry of Endovascular Treatment in Acute Stroke
- Author
-
Sallustio, Fabrizio, Pracucci, Giovanni, Cappellari, Manuel, Saia, Valentina, Mascolo, Alfredo Paolo, Marrama, Federico, Gandini, Roberto, Koch, Giacomo, Diomedi, Marina, D’Agostino, Federica, Rocco, Alessandro, Da Ros, Valerio, Wlderk, Andrea, Nezzo, Marco, Argirò, Renato, Morosetti, Daniele, Renieri, Leonardo, Nencini, Patrizia, Vallone, Stefano, Zini, Andrea, Bigliardi, Guido, Pitrone, Antonio, Grillo, Francesco, Bracco, Sandra, Tassi, Rossana, Bergui, Mauro, Naldi, Andrea, Carità, Giuseppe, Casetta, Ilaria, Gasparotti, Roberto, Magoni, Mauro, Simonetti, Luigi, Haznedari, Nicolò, Paolucci, Matteo, Mavilio, Nicola, Malfatto, Laura, Menozzi, Roberto, Genovese, Antonio, Cosottini, Mirco, Orlandi, Giovanni, Comai, Alessio, Franchini, Enrica, Pedicelli, Alessandro, Frisullo, Giovanni, Puglielli, Edoardo, Casalena, Alfonsina, Cester, Giacomo, Baracchini, Claudio, Castellano, Davide, Di Liberto, Alessandra, Ricciardi, Giuseppe Kenneth, Chiumarulo, Luigi, Petruzzellis, Marco, Lafe, Elvis, Persico, Alessandra, Cavasin, Nicola, Critelli, Adriana, Semeraro, Vittorio, Tinelli, Angelica, Giorgianni, Andrea, Carimati, Federico, Auteri, William, Rizzuto, Stefano, Biraschi, Francesco, Nicolini, Ettore, Ferrari, Antonio, Melis, Maurizio, Calia, Stefano, Tassinari, Tiziana, Nuzzi, Nunzio Paolo, Corato, Manuel, Sacco, Simona, Squassina, Guido, Invernizzi, Paolo, Gallesio, Ivan, Ruiz, Luigi, Dui, Giovanni, Carboni, Nicola, Amistà, Pietro, Russo, Monia, Maiore, Mario, Zanda, Bastianina, Craparo, Giuseppe, Mannino, Marina, Inzitari, Domenico, Toni, Danilo, Mangiafico, Salvatore, Gasparotti, R., Inzitari, D., Mangiafico, S., Toni, D., Vallone, S., Zini, A., Bergui, M., Causin, F., Ciccone, A., Nencini, P., Saletti, A., Sallustio, F., Tassi, R., Thyrion, F. Zappoli, Pracucci, G., Saia, V., Gandini, R., Da Ros, V., Greco, L., Morosetti, D., Diomedi, M., Nappini, S., Limbucci, N., Renieri, L., Fainardi, E., Verganti, L., Sacchetti, F., Zelent, G., Bigliardi, G., Dell’Acqua, M. L., Picchetto, L., Vandelli, L., Pentore, R., Maffei, S., Nichelli, P., Longo, M., Pitrone, A., Vinci, S. L., Velo, M., Caragliano, A., Tessitore, A., Bonomo, O., Musolino, R., La Spina, P., Casella, C., Fazio, M. C., Grillo, F., Cotroneo, M., Dell’Aera, C., Francalanza, I., Bracco, S., Cioni, S., Gennari, P., Vallone, I. M., Cerase, A., Martini, G., Stura, G., Daniele, D., Cerrato, P., Naldi, A., Onofrio, M., De Vito, A., Azzini, C., Casetta, I., Mardighian, D., Frigerio, M., Magoni, M., Costa, A., Simonetti, L., Cirillo, L., Taglialatela, F., Isceri, S., Princiotta, C., Dall’Olio, M., Cellerini, M., Gentile, M., Piccolo, L., Migliaccio, L., Brancaleoni, L., Naldi, F., Romoli, M., Zaniboni, A., Ruggiero, M., Sanna, A., Haznedari, N., Commodaro, C., Longoni, M., Biguzzi, S., Cordici, F., Malatesta, E., Castellan, L., Mavilio, N., Salsano, G., Malfatto, L., Finocchi, C., Menozzi, R., Piazza, P., Epifani, E., Andreone, A., Scoditti, U., Castellini, P., Latte, L., Grisendi, I., Cosottini, M., Puglioli, M., Lazzarotti, G., Lauretti, D., Mancuso, M., Giannini, N., Maccarone, M., Orlandi, G., Comai, A., Bonatti, G., Nano, G., Ferro, F., Bonatti, M., Dall’Ora, E., Dossi, R. Currò, Turri, E., Turri, M., Colosimo, C., Pedicelli, A., D’Argento, F., Alexandre, A., Frisullo, G., Di Egidio, V., Puglielli, E. G., Ruggero, L., Assetta, M., Casalena, A., Cester, G., Baracchini, C., Viaro, F., Pieroni, A., Vaudano, G., Comelli, C., Di Maggio, L., Castellano, D., Cavallo, R., Duc, E., Chianale, G., Ciceri, E. F. M., Plebani, M., Augelli, R., Zampieri, P., Grazioli, A., Cappellari, M., Forlivesi, S., Tomelleri, G., Micheletti, N., Chiumarulo, L., Zimatore, D. S., Federico, F., Petruzzelli, M., Zappoli, F., Lafe, E., Sanfilippo, G., Sgreccia, A., Martignoni, A., Cavallini, A., Denaro, F., Persico, A., Cagliari, E., Cavasin, N., Quatrale, R., Critelli, A., Burdi, N., Semeraro, V., Lucarelli, N., Ganimede, M. P., Internò, S., Tinelli, A., Prontera, M. P., Pesare, A., Cotroneo, E., Pampana, E., Ricciardi, F., Gigli, R., Pezzella, F. R., Corsi, F., Giorgianni, A., Baruzzi, F., Pellegrino, C., Terrana, A., Versino, M., Delodovici, M. L., Carimati, F., Cariddi, L. Princiotta, Auteri, W., Di Benedetto, O., Silvagni, U., Perrotta, P., Crispino, E., Petrone, A., Stancati, F., Rizzuto, S., Pugliese, P., Pisani, E., Siniscalchi, A., Gaudiano, C., Pirritano, D., Del Giudice, F., Piano, M., Agostoni, E., Motto, C., Gatti, A., Guccione, A., Tortorella, R., Stecco, A., Guzzardi, G., Del Sette, B., Coppo, L., Baldan, J., Romano, D., Siani, A., Locatelli, G., Saponiero, R., Napolitano, R., De Gregorio, M., Volpe, G., Tenuta, M., Guidetti, G., Biraschi, F., Wulbek, A., Falcou, A., Anzini, A., Mancini, A., De Michele, M., Fausti, S., Di Mascio, M. T., Durastanti, L., Sbardella, E., Mellina, V., Nicolini, E., Comelli, S., Ganau, C., Corraine, S., Fusaro, F., Ferrari, A., Schirru, F., Ledda, V., Secci, S., Melis, M., Piras, V., Moller, J., Padolecchia, R., Allegretti, L., Caldiera, V., Calia, S., Ganci, G., Tassinari, T., Sugo, A., De Nicola, M., Giannoni, M., Bruni, S., Gambelli, E., Provinciali, L., Nuzzi, N. P., Marcheselli, S., Corato, M., Scomazzoni, F., Simionato, F., Roveri, L., Filauri, P., Sacco, S., Orlandi, B., De Santis, F., Tiseo, C., Notturno, F., Ornello, R., Pavia, M., Squassina, G., Cobelli, M., Morassi, M., Magni, E., Invernizzi, P., Pepe, F., Bigni, B., Costa, P., Crabbio, M., Griffini, S., Palmerini, F., Piras, M. P., Gallesio, I., Barbero, S., Ferrandi, D., Dui, G., Fancello, M. C., Zedda, S., Ticca, A., Saddi, M. V., Deiana, G., Rossi, R., Carboni, N., Mela, A., Amistà, P., Russo, M., Iannucci, G., Pinna, V., Di Clemente, L., Santi, M., De Boni, A., De Luca, C., Natrella, M., Fanelli, G., Cristoferi, M., Bottacchi, E., Corso, G., Tosi, P., Sessa, M., Giossi, A., Baietti, Null, Romano, G., Meineri, P., Armentano, A., Versace, P., Arcudi, L., Galvano, G., Petralia, B., Feraco, P., Luppi, G., Giometto, B., Bignamini, V., Piffer, S., Meloni, G. B., Fabio, C., Maiore, M., Pintus, F., Pischedda, A., Manca, A., Mongili, C., Zanda, B., Baule, A., Florio, F., Ciccarese, G., Leone, M., Di Viesti, P., Pappalardo, M. P., Craparo, G., Gallo, C., Monaco, S., Mannino, M., Muto, M., Guarnieri, Gl., Andreone, V., Passalacqua, G., Allegritti, M., Caproni, S., Filizzolo, M., Salmaggi, A., Giordano, A., Marini, C., Frattale, I., Lucente, G., Nozzoli, C., and Lupo, F. A.
- Subjects
Stent ,Acute stroke ,Settore MED/37 - Neuroradiologia ,Acute stroke Internal carotid artery diseases Stent Thrombectomy ,Neurology (clinical) ,General Medicine ,Settore MED/26 ,Internal carotid artery diseases ,Thrombectomy - Abstract
The management of tandem extracranial internal carotid artery and intracranial large vessel occlusion during endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) has been under-investigated. We sought to investigate outcomes of AIS patients with tandem occlusion (TO) treated with carotid artery stenting (CAS) compared to those not treated with CAS (no-CAS) during EVT.We performed a cohort study using data from AIS patients enrolled in the Italian Registry of Endovascular Treatment in Acute Stroke. Outcomes were 3 months' mortality, functional outcome, complete and successful recanalization, any intracranial hemorrhage, parenchymal hematoma and symptomatic intracerebral hemorrhage.Among 466 AIS patients with TO, CAS patients were 122 and no-CAS patients were 226 (118 excluded). After adjustment for unbalanced variables, CAS was associated with a lower rate of 3 months' mortality (OR 0.407, 95% CI 0.171-0.969, p = 0.042). After adjustment for pre-defined variables, CAS was associated with a lower rate of 3 months' mortality (aOR 0.430, 95% CI 0.187-0.989, p = 0.047) and a higher rate of complete recanalization (aOR 1.986, 95% CI 1.121-3.518, p = 0.019), successful recanalization (aOR 2.433, 95% CI 1.263-4.686, p = 0.008) and parenchymal hematoma (aOR 2.876, 95% CI 1.173-7.050, p = 0.021). CAS was associated with lower 3 months mortality (OR 0.373, 95% CI 0.141-0.982, p = 0.046) and higher rates of successful recanalization (OR 2.082, 95% CI 1.099-3.942, p = 0.024) after adjustment for variables associated with 3 months' mortality and successful recanalization, respectively.Among AIS patients with TO, CAS during EVT was associated with a higher rate of successful reperfusion and a lower rate of 3 months' mortality.
- Published
- 2022
5. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency
- Author
-
Cugno, M., Zanichelli, A., Bellatorre, A. G., Griffini, S., and Cicardi, M.
- Published
- 2009
6. Severe chronic urticaria is associated with elevated plasma levels of D-dimer
- Author
-
Asero, R., Tedeschi, A., Riboldi, P., Griffini, S., Bonanni, E., and Cugno, M.
- Published
- 2008
7. Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype
- Author
-
Dalla Volta, G., Guindani, M., Zavarise, P., Griffini, S., Pezzini, A., and Padovani, A.
- Published
- 2005
- Full Text
- View/download PDF
8. Bearable maximum seismic action for existing concrete dams by Italian standards
- Author
-
Colombo, Martina, Domaneschi, M., Ghisi, A., and Griffini, S.
- Subjects
maximum earthquake ,sliding ,concrete dams, standards, finite elements, maximum earthquake, sliding, rock-mass ,standards ,finite elements ,rock-mass ,concrete dams - Published
- 2018
9. Influence of sumatriptan on the autonomic system during migraine attacks
- Author
-
Dalla Volta, G., Griffini, S., and Pezzini, A.
- Published
- 2006
- Full Text
- View/download PDF
10. SAT0655 Early endothelial damage in patients with raynaud's phenomenon
- Author
-
Gualtierotti, R, primary, Ingegnoli, F, additional, Schioppo, T, additional, Griffini, S, additional, Grovetti, E, additional, Borghi, MO, additional, Cugno, M, additional, and Meroni, PL, additional
- Published
- 2017
- Full Text
- View/download PDF
11. La triade personale sanitario - paziente - familiari in ambito neurologico e neurochirurgico. Risultati di un'indagine sul campo
- Author
-
Gandolfini, M., Conti, Adelaide, Delbon, Paola, Donati, E., Griffini, S., and Pasqualetti, P.
- Subjects
rapporto personale sanitario - paziente - familiari ,informazione ,comunicazione ,neurologia - Published
- 2014
12. Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders
- Author
-
Marconi, R., Grasso, L., Antonini, A., De Gaspari, D., Barone, P., Santangelo, G., Colosimo, C., Meco, G., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, M. G., Ceravolo, R., Cicarelli, G., Gaglio, R. M., Giglia, L., Iemolo, F., Manfredi, M., Nicoletti, A., Pederzoli, M., Petrone, A., Pisani, A., Pontieri, F. E., Quatrale, R., Ramat, S., Scala, R., Volpe, G., Zappulla, S., Bentivoglio, R., Stocchi, F., Trianni, G., Del Dotto, P., Morgante, F., Morgante, L., Fabbrini, G., Benincasa, D., Sensi, M., Braga, M., Capecci, M., Caravona, N., D'Asta, G., De Falco, F. A., Pezzoli, G., Di Giovanni, M., Floris, G., Gallerini, S., Gurgone, G., Frosini, D., Meoni, S., Savica, R., Moschella, V., Pepe, F., Petretta, V., Randisi, M. G., Romeno, M., Picillo, M., Sorbello, V., Tiple, D., Guidubaldi, A., Muoio, R., Toni, V., Logi, C., Bartalini, S., Ulivelli, M., Perini, M., Lanfranchi, S., Griffini, S., Troianiello, B., Baratti, M., Amidei, S., Consoli, D., Iellamo, M., Cuomo, T., Scaglioni, A., Medici, D., Abbruzzese, G., Di Brigida, G., Cocco, G. A., Agnetti, V., Cossu, G., Deriu, M., Abrignani, M., Modica, C., Albani, G., Pradotto, L., Martinelli, P., Scaglione, C., Mucchiut, M., Zanini, S., Pennisi, F., Soliveri, P., Albanese, A., Bartolomei, L., L'Erario, R., Capus, L., Ferigo, L., Marano, R., Nastasi, V., Luciano, R., Maiello, L., Simone, P., Fogli, D., Lopiano, L., Pesare, M., Nordera, G., Pilleri, E., Scaravilli, T., Giaccaglini, E., Alesi, C., Corbetta, T., Sgarbi, S., Rapisarda, A., Rizzoli, S., Zanoli, L., Manfredi, A., Marconi, R, Antonini, A, Barone, P, Colosimo, C, Avarello, Tp, Bottacchi, E, Cannas, A, Ceravolo, Mg, Ceravolo, R, Cicarelli, G, Gaglio, Rm, Giglia, L, Iemolo, F, Manfredi, M, Meco, G, Nicoletti, A, Pederzoli, M, Petrone, A, Pisani, A, Pontieri, Fe, Quatrale, R, Ramat, S, Scala, R, Volpe, G, Zappulla, S, Bentivoglio, Ar, Stocchi, F, Trianni, G, Del Dotto, P, De Gaspari, D, Grasso, L, Morgante, F, Santangelo, Gabriella, Fabbrini, G, Morgante, L, and PRIAMO study, Group
- Subjects
Questionnaires ,Lung Diseases ,Male ,Aged ,Aged, 80 and over ,Attention Deficit Disorder with Hyperactivity ,Cardiovascular Diseases ,Cognition Disorders ,Fatigue ,Female ,Frontal Lobe ,Gastrointestinal Diseases ,Humans ,Kidney Diseases ,Logistic Models ,Longitudinal Studies ,Middle Aged ,Parkinsonian Disorders ,Predictive Value of Tests ,Skin Diseases ,Sleep Wake Disorders ,Surveys and Questionnaires ,Neuropsychological Tests ,2708 ,Neurology (clinical) ,Psychiatry and Mental Health ,Neurology ,Disease ,Logistic regression ,Parkinson and cognitive impairment ,80 and over ,Verbal fluency test ,Neuroradiology ,Sleep Disorders ,General Medicine ,non-motor symptoms ,Psychiatry and Mental health ,Settore MED/26 - NEUROLOGIA ,Frontal lobe ,Predictive value of tests ,Psychology ,medicine.medical_specialty ,Dermatology ,behavioral disciplines and activities ,Internal medicine ,medicine ,Psychiatry ,Surrogate endpoint ,Frontal functions ,Non-motor symptoms ,frontal functions ,parkinson and cognitive impairment - Abstract
Using data from the PRIAMO study, we investigated non-motor symptoms (NMS) versus frontal lobe dysfunction in patients with idiopathic Parkinson disease (PD); 808 patients with PD and 118 with atypical parkinsonisms (AP) were consecutively enrolled at 55 Centers in Italy. Twelve categories of NMS were investigated. Cognitive impairment was defined as a Mini-Mental Status Evaluation score ≤ 23.8 and frontal lobe dysfunction as a Frontal Assessment Battery (FAB) score ≤ 3.48. Multivariable logistic regression was used to identify predictor of frontal lobe dysfunction in 524 PD patients, and a generalized linear model was used for each of the six FAB items. Not only the total FAB scores but also the single FAB items were lower in AP versus PD (p ≤ 0.005). Age (OR = 1.05), cognitive impairment (OR = 9.54), lack of cardiovascular symptoms (OR = 3.25), attention or memory problems (OR = 0.59) and treatment with L: -DOPA (OR = 5.58) were predictors of frontal lobe dysfunction. MMSE was negatively associated with all FAB items (β ≤ -0.16) and age with all FAB items but prehension behavior (β ≤ -0.01). Previous use of L: -DOPA was negatively associated with verbal fluency (β = -0.32) possibly acting as surrogate marker of disease duration. Cognitive impairment is a predictor of frontal lobe dysfunction. Among NMS, lack of attention or memory problems were negatively associated with frontal impairment. Further studies are nonetheless needed to better identify the predictors of frontal impairment in PD patients.
- Published
- 2012
13. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study
- Author
-
Colosimo, C, Morgante, L, Antonini, A, Barone, P, Avarello, Tp, Bottacchi, E, Cannas, A, Ceravolo, Mg, Ceravolo, R, Cicarelli, G, Gaglio, Rm, Giglia, L, Iemolo, F, Manfredi, M, Meco, G, Nicoletti, A, Pederzoli, M, Petrone, A, Pisani, A, Pontieri, Fe, Quatrale, R, Ramat, S, Scala, R, Volpe, G, Zappulla, S, Bentivoglio, Ar, Stocchi, F, Trianni, G, Del Dotto, P, Simoni, L, Marconi, R, Priamo, Sg, Benincasa, D, Biguzzi, S, Braga, M, Capecci, M, Caravona, N, D'Asta, G, De Falco, Fa, De Gaspari, D, Pezzoli, G, Di Giovanni, M, Floris, G, Gallerini, S, Grasso, L, Gurgone, G, Kiferle, L, Meoni, S, Morgante, F, Savica, R, Moschella, V, Pepe, F, Petretta, V, Randisi, Mg, Romeno, M, Santangelo, G, Ianniciell, M, Sorbello, V, Fabbrini, G, Berardelli, A, Guidubaldi, A, Muoio, R, Toni, V, Logi, C, Ciacci, G, Ulivelli, M, Perini, M, Lanfranchi, S, Griffini, S, Troianiello, B, Baratti, M, Amidei, S, Consoli, D, Iellamo, M, Cuomo, T, Scaglioni, A, Medici, D, Abbruzzese, Giovanni, Di Brigida, G, Cocco, Ga, Agnetti, V, Cossu, G, Deriu, M, Abrignani, M, Modica, C, Albani, G, Milan, E, Martinelli, P, Scaglione, C, Mucchiut, M, Zanini, S, Pennisi, F, Soliveri, P, Albanese, A, Bartolomei, L, L'Erario, R, Capus, L, Ferigo, L, Marano, R, Nastasi, V, Luciano, R, Maiello, L, Simone, P, Fogli, D, Lopiano, L, Pesare, M, Nordera, G, Pilleri, E, Scaravilli, T, Giaccaglini, E, Alesi, C, Corbetta, T, Dumitriu, A, Sgarbi, S, Rapisarda, A, Rizzoli, S, Zanoli, L, Manfredi, A., Colosimo C., Morgante L., Antonini A., Barone P., Avarello T.P., Bpttacchi E., Cannas A., Ceravolo M.G., Ceravolo R., Cicarelli G., Gaglio R.M., Giglia L., Iemolo F., Manfredi M., Meco G., Nicoletti A., Pederzoli M., Petrone A., Pisani A., Pontieri FE., Quatrale r., Ramat S., Scala R., Volpe G., Zappulla S., Bentivoglio A.R., Stocchi F., Trianni G., Del Dotto P., Simoni L., Marconi R., PRIAMO STUDY GROUP [.., Martinelli P., ], Colosimo, C, Morgante, L, Antonini, A, Barone, Paolo, Avarello, Tp, Bottacchi, E, Cannas, A, Ceravolo, Mg, Ceravolo, R, Cicarelli, G, Gaglio, Rm, Giglia, L, Iemolo, F, Manfredi, M, Meco, G, Nicoletti, A, Pederzoli, M, Petrone, A, Pisani, A, Pontieri, Fe, Quatrale, R, Ramat, S, Scala, R, Volpe, G, Zappulla, S, Bentivoglio, Ar, Stocchi, F, Trianni, G, Del Dotto, P, Simoni, L, Marconi, R, and PRIAMO STUDY, G. R. O. U. P.
- Subjects
Male ,Secondary ,Neurology ,secondary parkinsonism ,parkinson and cognitive impairment ,Neurological disorder ,PRIAMO STUDY ,Orthostatic vital signs ,Prevalence ,Corticobasal degeneration ,Supranuclear Palsy ,Longitudinal Studies ,Parkinsonism ,Cognitive disorder ,Parkinson Disease ,Neurodegenerative Diseases ,Middle Aged ,non-motor symptoms ,atypical parkinsonism ,Italy ,Atypical parkinsonism, Non-motor symptoms, Parkinson and cognitive impairment, Secondary parkinsonism ,epidemiology ,Settore MED/26 - Neurologia ,Female ,Supranuclear Palsy, Progressive ,Lewy Body Disease ,medicine.medical_specialty ,Humans ,Aged ,Parkinson Disease, Secondary ,Cross-Sectional Studies ,Multiple System Atrophy ,Parkinsonian Disorders ,Atypical parkinsonism ,Non-motor symptoms ,Parkinson and cognitive impairment ,Secondary parkinsonism ,Neurology (clinical) ,Aged, Cross-Sectional Studies, Female, Humans, Italy ,epidemiology, Lewy Body Disease ,epidemiology, Longitudinal Studies, Male, Middle Aged, Multiple System Atrophy ,epidemiology, Neurodegenerative Diseases ,epidemiology, Parkinson Disease ,epidemiology, Parkinsonian Disorders ,epidemiology, Prevalence, Supranuclear Palsy ,Progressive ,Progressive supranuclear palsy ,Internal medicine ,mental disorders ,medicine ,Dementia with Lewy bodies ,business.industry ,medicine.disease ,nervous system diseases ,Physical therapy ,business ,PARKINSONISM - Abstract
The PRIAMO study is a cross-sectional longitudinal observational study aimed at describing epidemiology and evolution of non-motor symptoms (NMS) in patients with different forms of parkinsonism recruited in 55 Italian centres and evaluated over 24 months. In this paper, we are reporting prevalence and clinical characteristics of NMS in patients with atypical and secondary parkinsonism. Out of 1307 consecutive patients with a diagnosis of parkinsonism, 83 patients had vascular parkinsonism (VP), 34 had multiple system atrophy (MSA), 30 had progressive supranuclear palsy (PSP), 14 had dementia with Lewy bodies (DLB) and 11 had corticobasal degeneration (CBD). MSA and DLB had the highest number of NMS domains and symptoms, respectively. Gastrointestinal symptoms, pain, urinary problems and postural instability due to orthostatic hypotension were most frequent in MSA. Sleep disturbances were also common with a prevalence of approximately 70% in all diagnostic groups but CBD (36%). Psychiatric symptoms and attention and memory impairment were frequently observed in all diagnoses but were most prevalent among DLB patients, whereas the prevalence of skin and respiratory disorders was rather low in all forms, ranging between 10 and 30%. Atypical parkinsonism patients also reported a low QoL, with no significant differences among the different forms, whereas PD and VP patients had a better QoL.
- Published
- 2009
14. Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study
- Author
-
Santangelo, G, Morgante, L, Savica, R, Marconi, R, Grasso, L, Antonini, A, De Gaspari, D, Ottaviani, D, Tiple, D, Simoni, L, Barone, P, Priamo, Sg, Colosimo, C, Benincasa, D, Biguzzi, S, Braga, M, Capecci, M, Caravona, N, De Falco, Fa, Pezzoli, G, Di Giovanni, M, Floris, G, Gallerini, S, Gurgone, G, Kiferle, L, Meoni, S, Moschella, V, Morgante, F, Pepe, F, Petretta, V, Randisi, Mg, Romeno, M, Ianniciello, M, Sciortino, G, Guzzardi, Po, Sorbello, V, Fabbrini, G, Guidubaldi, A, Muoio, R, Toni, V, Ferrari, Po, Logi, C, Ciacci, G, Ulivelli, M, Perini, M, Lanfranchi, S, Griffini, S, Troianiello, B, Baratti, M, Amidei, S, Consoli, D, Iellamo, M, Cuomo, T, Scaglioni, A, Medici, D, Abbruzzese, Giovanni, Di Brigida, G, Cocco, Ga, Agnetti, V, Cossu, G, Deriu, M, Abrignani, M, Modica, C, Albani, G, Milan, E, Martinelli, P, Scaglione, C, Mucchiut, M, Zanini, S, Pennisi, F, Soliveri, P, Albanese, A, Bartolomei, L, L'Erario, R, Capus, L, Ferigo, L, Marano, R, Nastasi, V, Luciano, R, Maiello, L, Simone, P, Fogli, D, Lopiano, L, Pesare, M, Molinette, As, Nordera, G, Pilleri, E, Scaravilli, T, Giaccaglini, E, Alesi, C, Corbetta, T, Dumitriu, A, Ingelheim, B, Sgarbi, S, Rapisarda, A, Rizzoli, S, Zanoli, L, Manfredi, A., Santangelo, Gabriella, Morgante, L, Savica, R, Marconi, R, Grasso, L, Antonini, A, De Gaspari, D, Ottaviani, D, Tiple, D, Simoni, L, Barone, P, PRIAMO Study, Group, Santangelo, G, Barone, Paolo, and PRIAMO Study, G. r. o. u. p.
- Subjects
Male ,medicine.medical_specialty ,Parkinson's disease ,media_common.quotation_subject ,Multilingualism ,Pilot Projects ,Test validity ,Affect (psychology) ,behavioral disciplines and activities ,Aged, Aged ,80 and over, Cognition Disorders ,diagnosis/epidemiology/psychology, Depressive Disorder ,Major ,diagnosis/epidemiology/psychology, Female, Humans, Italy ,epidemiology, Male, Middle Aged, Multilingualism, Parkinson Disease ,diagnosis/epidemiology/psychology, Pilot Projects, Psychiatric Status Rating Scales ,standards, Reproducibility of Results ,Pleasure ,medicine ,80 and over ,Humans ,Psychiatry ,Depression (differential diagnoses) ,media_common ,Aged ,Aged, 80 and over ,Psychiatric Status Rating Scales ,Depressive Disorder, Major ,Depressive Disorder ,Parkinsonism ,Anhedonia ,Reproducibility of Results ,Parkinson Disease ,Middle Aged ,medicine.disease ,Test (assessment) ,Neurology ,Italy ,standards ,Female ,epidemiology ,Neurology (clinical) ,Geriatrics and Gerontology ,medicine.symptom ,Psychology ,Cognition Disorders ,diagnosis/epidemiology/psychology ,Clinical psychology - Abstract
To assess the psychometric properties of the Italian version of the Snaith-Hamilton Pleasure Scale (SHAPS) and to study the relationship between anhedonia, depression and cognitive impairment in patients with Parkinson's disease (PD).The SHAPS (14 items) was translated into Italian and pre-tested in a pilot study. Two items evaluating physical anhedonia related to sexual issues were added. The Italian version of SHAPS was validated in 274 consecutive PD patients, divided into patients with major depression according to DSM-IV criteria (dPD) and patients without depression (nPD), and in healthy subjects. To test the feasibility of the instrument and to determine whether clinical data affect anhedonia, we also administered SHAPS to 1307 patients with different types of parkinsonism.The Italian SHAPS proved to be easy to understand as regards the question and answer modes. Intraclass coefficient for test-retest reliability was 0.65 for the total score. KR index was 0.61. ANOVA of the SHAPS total score revealed that scores were higher in dPD patients than in healthy controls and nPD (p0.05). In the 1307 patients with various types of parkinsonism, the SHAPS data showed that anhedonia was related to age, type of parkinsonism, apathy, depression and cognitive impairment. Anhedonia was correlated with frontal dysfunctions in supranuclear palsy and PD patients (r=-0.682 and -0.264 respectively, p0.05).The Italian version of the SHAPS is a reliable tool with which to assess anhedonia in patients with PD and other forms of parkinsonism.
- Published
- 2009
15. Prevalence and size of PFO in migraine with and without aura and cluster headache and relation with clinical phenotype
- Author
-
Dalla Volta, G, Griffini, S, Pezzini, Alessandro, and Zavarise, P.
- Published
- 2007
16. Haemostatic and inflammatory biomarkers in patients with rheumatoid arthritis : effect of tumor necrosis factor alpha blockade
- Author
-
Cugno, M., Ingegnoli, F., Favalli, E., Soldi, A., Griffini, S., Bonanni, E., Galbiati, V., and Fantini, F.
- Subjects
Settore MED/16 - Reumatologia ,Settore MED/09 - Medicina Interna ,inflammation ,Rheumatoid arthritis ,Infliximab ,coagulation - Published
- 2007
17. Influence of allodynia and the autonomic system activation on the response to triptans in migraine
- Author
-
Dalla Volta, G, Griffini, S, Pezzini, Alessandro, and Zavarise, P.
- Published
- 2007
18. La compréhension orale en temps réel des auxiliaires chez des patients aphasiques
- Author
-
Griffini, S., Rigalleau, F., Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA), Université de Poitiers-Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), and Centre National de la Recherche Scientifique (CNRS)-Université de Tours-Université de Poitiers
- Subjects
[SCCO.PSYC]Cognitive science/Psychology - Published
- 2006
19. Clinical and thermographic evaluation of the trigemino-vascular system during migraine attacks in patients treated with triptans and/or ketoprophen
- Author
-
dalla Volta GD, Griffini, S, Pezzini, Alessandro, and Civelli, P.
- Published
- 2003
20. EFFECT OF INFLIXIMAB INFUSION ON THE ACTIVATION OF THE COAGULATION CASCADE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (IBD)
- Author
-
Ciscato, C., primary, Spina, L., additional, Cavallaro, F., additional, Griffini, S., additional, De Salvo, C., additional, Cugno, M., additional, and Vecchi, M., additional
- Published
- 2009
- Full Text
- View/download PDF
21. Severe chronic urticaria is associated with elevated plasma levels of D-dimer
- Author
-
Asero, R., primary, Tedeschi, A., additional, Riboldi, P., additional, Griffini, S., additional, Bonanni, E., additional, and Cugno, M., additional
- Published
- 2007
- Full Text
- View/download PDF
22. Plasmatic markers of acute attack in patients with angioedema due to C1 inhibitor deficiency
- Author
-
Zanichelli, A., primary, Cugno, M., additional, Griffini, S., additional, Maggioni, L., additional, Bellatorre, A.G., additional, Zingale, L.C., additional, and Cicardi, M., additional
- Published
- 2007
- Full Text
- View/download PDF
23. Plasmatic Markers Of Coagulation And Fibrinolysis In Patients With C1 Inhibitor Deficiency During Acute Attacks Of Angioedema
- Author
-
Zanichelli, A., primary, Cugno, M., additional, Zingale, L.C., additional, Lambertenghi Deliliers, D., additional, Maggioni, L., additional, Griffini, S., additional, and Cicardi, M., additional
- Published
- 2007
- Full Text
- View/download PDF
24. ID: 201 Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease
- Author
-
Cugno, M., primary, Saibeni, S., additional, Ciscato, C., additional, Vecchi, M., additional, Boscolo Anzoletti, M., additional, Griffini, S., additional, and de Franchis, R., additional
- Published
- 2006
- Full Text
- View/download PDF
25. Controllo con teletermografia dell'efficacia terapeutica dell'ossigeno-ozono terapia nel trattamento dei conflitti disco-radicolari
- Author
-
Dalla Volta, G., primary, Troianiello, B., additional, Griffini, S., additional, Bonetti, M., additional, and Valdenassi, L., additional
- Published
- 2001
- Full Text
- View/download PDF
26. Controllo con teletermografia dell'efficacia terapeutica dell'ossigeno-ozono terapia nel trattamento dei conflitti disco-radicolari
- Author
-
Dalla Volta, G., Troianiello, B., Griffini, S., Bonetti, M., and Valdenassi, L.
- Abstract
Sono stati valutati, tramite Teletermografia degli arti inferiori, 25 pazienti affetti da ernia discale lombo-sacrale sia prima che dopo intervento antalgico con Ozonoterapia. È stato così possibile ricercare una correlazione diretta tra le variazioni delle immagini termografiche (indice dell'attività del Sistema Nervoso Autonomico) e neuroradiologiche (TC rachide lombo-sacrale) e la variazione della sintomatologia algica riferita dal paziente prima e dopo l'intervento con ozonoterapia. In particolare, l'ipotermia rilevata dalla Teletermografia nel distretto cutaneo riferibile all'innervazione radicolare compromessa, si riduce o scompare in seguito a trattamento con ozonoterapia, solo nel caso vi sia una risoluzione parziale o completa del quadro clinico.
- Published
- 2001
- Full Text
- View/download PDF
27. Reduction of haemostatic and inflammatory biomarkers by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis
- Author
-
Ingegnoli, F., Massimo Cugno, Favalli, E., Soldi, A., Griffini, S., Bonanni, E., and Fantini, F.
28. Treatment with infliximab is associated with reduction of prothrombotic and inflammatory biomarkers in patients with rheumatoid arthritis
- Author
-
Ingegnoli, F., Massimo Cugno, Favalli, E. G., Soldi, A., Galbiati, V., Griffini, S., Bonanni, E., and Fantini, F.
29. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis
- Author
-
Ingegnoli F, Fantini F, Griffini S, Soldi A, Pier Luigi Meroni, and Cugno M
- Subjects
Adult ,Male ,Tumor Necrosis Factor-alpha ,Fibrinolysis ,Antibodies, Monoclonal ,Thrombosis ,Middle Aged ,Atherosclerosis ,Infliximab ,Arthritis, Rheumatoid ,Young Adult ,Methotrexate ,Risk Factors ,Antirheumatic Agents ,Humans ,Drug Therapy, Combination ,Female ,Biomarkers - Abstract
Rheumatoid arthritis (RA) is associated with increased cardiovascular risk and involvement of inflammation, coagulation and fibrinolysis. Treatment with infliximab, a tumour necrosis factor-alpha (TNF-alpha) blocking chimeric monoclonal antibody, induces a long-term reduction of inflammation and coagulation, but its effect on fibrinolysis is still unknown. We carried out an observational study investigating plasma biomarkers of inflammation and fibrinolysis in RA patients before and after 14 weeks of infliximab treatment given according to the therapeutic guidelines for RA.We studied 20 selected patients with active RA and without any other atherosclerosis risk factor as well as 40 healthy controls. Patients, treated with a stable dose of methotrexate, received infliximab (3 mg/kg) at week 0, 2, 6 and 14. At week 0 and 14, we assessed clinical, inflammatory and fibrinolyitic parameters.At baseline, plasminogen activator inhibitor (PAI-1) antigen, PAI-1 activity and tissue-type plasminogen activator (t-PA) antigen were significantly higher in RA patients than in controls (p=0.01, p=0.001 and p=0.0001 respectively). After 14 weeks of infliximab treatment, the levels of PAI-1 antigen, PAI-1 activity and t-PA antigen significantly decreased till normalization (p=0.0001). Plasma levels of C reactive protein (CRP) and interleukin-6 (IL-6) were directly correlated with levels of PAI-1 antigen (p=0.011 and p=0.0001), PAI-1 activity (p=0.013 and p=0.027) and t-PA antigen (p=0.017 and p=0.040).This study provides evidence that TNF-alpha blockade by infliximab not only decreases inflammation, but also reduces the inhibition of fibrinolysis. Such a combined effect may be pivotal in reducing the whole thrombotic risk in these patients.
30. Prothrombotic biomarkers in patients with rheumatoid arthritis: The beneficial effect of IL-6 receptor blockade
- Author
-
Gualtierotti, R., Francesca Ingegnoli, Griffini, S., Grovetti, E., Meroni, P. L., and Cugno, M.
31. Anti-tumour necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis
- Author
-
Francesca Ingegnoli, Fantini, F., Griffini, S., Soldi, A., Meroni, P. L., and Cugno, M.
32. Activation of inflammation, coagulation and fibrinolysis in patients with rheumatoid arthritis: Inhibition by tumour necrosis factor alpha blockade
- Author
-
Francesca Ingegnoli, Fantini, F., Favalli, E., Galbiati, V., Soldi, A., Griffini, S., Bonanni, E., and Cugno, M.
33. Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
- Author
-
Giacomo P. Comi, Massimo Cugno, Sara Bonato, Pier Luigi Meroni, Luca De Maso, Mara Giordano, Samantha Griffini, Andrea Artoni, Elena Grovetti, Flora Peyvandi, Paolo Macor, Simona Mellone, Daniele Prati, Luca Valenti, Marcello Manfredi, Cugno, M., Macor, P., Giordano, M., Manfredi, M., Griffini, S., Grovetti, E., De Maso, L., Mellone, S., Valenti, L., Prati, D., Bonato, S., Comi, G., Artoni, A., Meroni, P. L., and Peyvandi, F.
- Subjects
Adult ,COVID-19 Vaccines ,Vaccine-induced thrombotic thrombocytopenia ,COVID-19 Vaccine ,Immunology ,Complement ,Anti-PF4 antibodie ,Complement Membrane Attack Complex ,Platelet Factor 4 ,Mannose-Binding Lectin ,Classical complement pathway ,ChAdOx1 nCoV-19 ,Immunology and Allergy ,Medicine ,Humans ,Complement Pathway, Classical ,Purpura ,Autoantibodies ,Anti-PF4 antibodies ,COVID-19 ,Female ,Complement C2 ,Complement Pathway, Mannose-Binding Lectin ,Purpura, Thrombotic Thrombocytopenic ,SARS-CoV-2 ,Thrombotic Thrombocytopenic ,biology ,Complement component 2 ,business.industry ,Autoantibodie ,Complement system ,Classical ,Complement Pathway ,Lectin pathway ,biology.protein ,Alternative complement pathway ,Antibody ,business ,Complement membrane attack complex ,Platelet factor 4 ,Human - Abstract
Extremely rare reactions characterized by thrombosis and thrombocytopenia have been described in subjects that received ChAdOx1 nCoV-19 vaccination 5-16 days earlier. Although patients with vaccine-induced thrombotic thrombocytopenia (VITT) have high levels of antibodies to platelet factor 4 (PF4)-polyanion complexes, the exact mechanism of the development of thrombosis is still unknown. Here we reported serum studies as well as proteomics and genomics analyses demonstrating a massive complement activation potentially linked to the presence of anti-PF4 antibodies in a patient with severe VITT. At admission, complement activity of the classical and lectin pathways were absent (0% for both) with normal levels of the alternative pathway (73%) in association with elevated levels of the complement activation marker sC5b-9 (630 ng/mL [n.v. 139-462 ng/mL]) and anti-PF4 IgG (1.918 OD [n.v. 0.136-0.300 OD]). The immunoblotting analysis of C2 showed the complete disappearance of its normal band at 110 kDa. Intravenous immunoglobulin treatment allowed to recover complement activity of the classical pathway (91%) and lectin pathway (115%), to reduce levels of sC5b-9 (135 ng/mL) and anti-PF4 IgG (0.681 OD) and to normalize the C2 pattern at immunoblotting. Proteomics and genomics analyses in addition to serum studies showed that the absence of complement activity during VITT was not linked to alterations of the C2 gene but rather to a strong complement activation leading to C2 consumption. Our data in a single patient suggest monitoring complement parameters in other VITT patients considering also the possibility to target complement activation with specific drugs.
- Published
- 2021
34. The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease
- Author
-
L Grasso, Silvia Ramat, Simone Gallerini, Paolo Barone, G. Di Brigida, D. Fogli, Tommaso Scaravilli, M. Braga, Alessandra Nicoletti, M. Romeno, Paolo Martinelli, G. Gurgone, Cesare Colosimo, E. Pilleri, V. Sorbello, S. Amidei, F. Pennisi, Francesco Iemolo, Giorgio Trianni, Vincenzo Toni, E. Milan, Raffaele Palladino, D. Benincasa, Giovanni Pezzoli, M. G. Randisi, Alfredo Petrone, Arianna Guidubaldi, R. Alfano, Tania P. Avarello, A. Scaglioni, Anna Rita Bentivoglio, C. Modica, L. Ferigo, M. Manfredi, Domenico Consoli, Giuseppe Meco, Giampiero Volpe, S. Griffini, Francesca Morgante, R. Scala, G. Nordera, Angelo Antonini, G. Floris, Roberto Erro, R. Muoio, Salvatore Zappulla, Luigi Bartolomei, Edo Bottacchi, Antonio Pisani, V. Petretta, Giovanni Fabbrini, G. Ciacci, L. Maiello, G. Ceravolo, M. Di Giovanni, V. Nastasi, Rocco Quatrale, D. Tiple, Marcello Deriu, S. Lanfranchi, Marianna Capecci, Alberto Albanese, T. Cuomo, Francesco E. Pontieri, Vincenzo Moschella, G. Sciortino, F. A. De Falco, S. Biguzzi, Leonardo Lopiano, Marina Picillo, C. Alesi, D. De Gaspari, Michele Abrignani, Gabriella Santangelo, Fabrizio Stocchi, R. Luciano, M. Baratti, R. M. Giglia, Cesa Scaglione, B. Troianiello, Giovanni Abbruzzese, M. Mucchiut, F. Pepe, S. Zanini, L. Capus, N. Caravona, Giovanni Cossu, V. Agnetti, G. Albani, L. Kiferle, E. Giaccaglini, Roberto Marconi, M. Iellamo, R. Marano, D. Medici, Monica Ulivelli, G. A. Cocco, M. Perini, P. Del Dotto, Rosa M. Gaglio, Rodolfo Savica, C. Logi, G. Ciccarelli, P. Massimo, M. Pesare, Antonino Cannas, Roberto Ceravolo, P. Simone, Letterio Morgante, P. Soliveri, S. Meoni, Picillo, M., Palladino, R., Erro, R., Alfano, R., Colosimo, C., Marconi, R., Antonini, A., Barone, P., Morgante, L., Benincasa, D., Quatrale, R., Biguzzi, S., Braga, M., Ceravolo, G., Capecci, M., Meco, G., Caravona, N., Scala, R., De Falco, F. A., Pezzoli, G., De Gaspari, D., Bottacchi, E., Di Giovanni, M., Cannas, A., Floris, G., Gallerini, S., Grasso, L., Gaglio, R. M., Gurgone, G., Volpe, G., Zappulla, S., Ceravolo, R., Kiferle, L., Ramat, S., Meoni, S., Pisani, A., Moschella, V., Morgante, F., Savica, R., Pepe, F., Ciccarelli, G., Petretta, V., Giglia, R. M., Randisi, M. G., Iemolo, F., Avarello, T. P., Romeno, M., Santangelo, G., Stocchi, F., Sciortino, G., Sorbello, V., Nicoletti, A., Tiple, D., Fabbrini, G., Bentivoglio, A., Pontieri, F. E., Guidubaldi, A., Muoio, R., Toni, V., Del Dotto, P., Logi, C., Ciacci, G., Ulivelli, M., Perini, M., Lanfranchi, S., Griffini, S., Troianiello, B., Baratti, M., Amidei, S., Consoli, D., Iellamo, M., Cuomo, T., Scaglioni, A., Medici, D., Manfredi, M., Abbruzzese, G., Di Brigida, G., Cocco, G. A., Agnetti, V., Cossu, G., Deriu, M., Abrignani, M., Modica, C., Albani, G., Milan, E., Martinelli, P., Scaglione, C., Mucchiut, M., Zanini, S., Pennisi, F., Soliveri, P., Albanese, A., Massimo, P., Bartolomei, L., Capus, L., Ferigo, L., Marano, R., Nastasi, V., Luciano, R., Maiello, L., Simone, P., Fogli, D., Lopiano, L., Pesare, M., Nordera, G., Pilleri, E., Scaravilli, T., Giaccaglini, E., Alesi, C., Petrone, A., and Trianni, G.
- Subjects
Male ,Neurology ,Parkinson's disease ,Constipation ,Heterogeneity ,Parkinson ,Phenotype ,Prodromal ,Sex ,PROGRESSION ,Disease ,0302 clinical medicine ,Apathy ,Neuroradiology ,Original Communication ,Cognition ,Parkinson Disease ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,NONMOTOR SYMPTOMS ,Life Sciences & Biomedicine ,PRIAMO study group ,Human ,medicine.medical_specialty ,Clinical Neurology ,Prodromal Symptoms ,Prodromal Symptom ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Clinical phenotype ,Aged ,Science & Technology ,Neurology & Neurosurgery ,business.industry ,1103 Clinical Sciences ,Biomarker ,medicine.disease ,DYSFUNCTION ,Biomarkers ,Neurology (clinical) ,Neurosciences & Neurology ,business ,1109 Neurosciences ,030217 neurology & neurosurgery - Abstract
Objectives To explore the impact of sex and age on relationship between prodromal constipation and disease phenotype in Parkinson’s disease at early stages. Methods A total of 385 Parkinson’s disease patients from the PRIAMO study were classified according to the presence of prodromal constipation and followed for 24 months. Multivariable mixed-effect models were applied. All analyses were performed separately for sex (64.1% men) and median age (different by sex: 67 years-old in men and 68 years-old in women). Results As for sex, prodromal constipation was associated with greater odds of attention/memory complaints and apathy symptoms in women only. As for age, prodromal constipation was associated with lower cognitive and higher apathy scores in older patients only. Conclusions Prodromal constipation anticipates lower cognitive performances and more severe apathy since the earliest stages in women and older patients. Sex- and age-related heterogeneity of prodromal markers of Parkinson’s disease may impact disease phenotype.
- Published
- 2021
35. Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk
- Author
-
Massimo Cugno, Alberto Tedeschi, Angelo V. Marzano, Samantha Griffini, Alessandro Borghi, Luigia Venegoni, Paolo Bucciarelli, Riccardo Asero, Elena Grovetti, Emilio Berti, Cugno, M, Tedeschi, A, Borghi, A, Bucciarelli, P, Asero, R, Venegoni, L, Griffini, S, Grovetti, E, Berti, E, and Marzano, A
- Subjects
Adult ,Male ,Pemphigoid ,Urticaria ,medicine.drug_class ,lcsh:Medicine ,Socio-culturale ,Skin Diseases ,Autoimmune Diseases ,Thromboplastin ,Fibrin Fibrinogen Degradation Products ,Young Adult ,Tissue factor ,MED/35 - MALATTIE CUTANEE E VENEREE ,Pemphigoid, Bullous ,Blood plasma ,medicine ,Humans ,lcsh:Science ,skin and connective tissue diseases ,Skin ,Skin Tests ,Biochemistry, Genetics and Molecular Biology (all) ,Multidisciplinary ,integumentary system ,business.industry ,Medicine (all) ,lcsh:R ,Anticoagulant ,Thrombosis ,AUTOIMMUNE CHRONIC URTICARIA ,Middle Aged ,medicine.disease ,Peptide Fragments ,BULLOUS PEMPHIGOID ,eye diseases ,Pathophysiology ,Agricultural and Biological Sciences (all) ,Coagulation ,Immunology ,Female ,Prothrombin ,lcsh:Q ,BLOOD COAGULATION ,Bullous pemphigoid ,BLOOD COAGULATION, AUTOIMMUNE CHRONIC URTICARIA, BULLOUS PEMPHIGOID ,business ,Research Article - Abstract
Coagulation activation has been demonstrated in two prototypic autoimmune skin diseases, chronic autoimmune urticaria and bullous pemphigoid, but only the latter is associated with increased thrombotic risk. Two markers of coagulation activation (prothrombin fragment F1+2 and fibrin fragment D-dimer) were measured by immunoenzymatic methods in plasma samples from 30 patients with active chronic autoimmune urticaria, positive for autologous serum skin test, 30 patients with active bullous pemphigoid and 30 healthy subjects. In skin biopsies, tissue factor expression was evaluated by both immunohistochemistry and in situ hybridization. F1+2 and D-dimer levels were higher in active chronic autoimmune urticaria (276.5±89.8 pmol/L and 5.56±4.40 nmol/L, respectively) than in controls (145.2±38.0 pmol/L and 1.06±0.25 nmol/L; P=0.029 and P=0.011) and were much higher in active bullous pemphigoid (691.7±318.7 pmol/L and 15.24±9.09 nmol/L, respectively) (P
- Published
- 2015
36. Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.
- Author
-
Ardissino G, Cresseri D, Mancuso MC, Capone V, Porcaro L, Amico V, Tangredi M, Grovetti E, Griffini S, Castellano G, Montini G, Consonni D, and Cugno M
- Subjects
- Humans, Male, Female, Adult, Treatment Outcome, Kidney Failure, Chronic etiology, Complement Inactivating Agents therapeutic use, Retrospective Studies, Adolescent, Young Adult, Recurrence, Middle Aged, Complement Activation drug effects, Child, Risk Factors, Time Factors, Atypical Hemolytic Uremic Syndrome drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Complement C5 antagonists & inhibitors
- Abstract
Background: Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizumab has improved the outcome, however, its efficacy varies among patients and its discontinuation is debated., Methods: To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormalities and/or triggers at onset in 4 categories: (1) primary (complement abnormality without trigger), (2) secondary (trigger without complement abnormality), (3) combined (trigger and complement abnormality), (4) idiopathic (no trigger, no complement abnormality). Response to treatment was evaluated by comparing the response to eculizumab with that of conventional therapy. Short- and long-term outcomes were evaluated with the relapse rate after discontinuation of C5-inhibition., Results: Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazard ratio 0.25, 95% confidence interval: 0.10-0.80). The excellent global response was driven by the primary and combined groups (89.8% vs 54.0% and 89.3% vs 54.2%, respectively). The relapse rate following discontinuation of the C5-inhibitor was as high as 66.7% in the primary group, 18.7% in the combined, and 0% in the secondary and idiopathic groups., Conclusions: Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed in the secondary and idiopathic forms., (© 2024. The Author(s) under exclusive licence to Italian Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
37. Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura.
- Author
-
Cugno M, Mancini I, Consonni D, De Zan V, Ardissino G, Griffini S, Grovetti E, Porcaro L, Ferrari B, Artoni A, and Peyvandi F
- Subjects
- Humans, Complement Activation, ADAMTS13 Protein, Purpura, Thrombotic Thrombocytopenic complications, Kidney Diseases
- Published
- 2023
- Full Text
- View/download PDF
38. Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.
- Author
-
Cugno M, Meroni PL, Consonni D, Griffini S, Grovetti E, Novembrino C, Torri A, Griffante G, Gariglio M, Varani L, and Peyvandi F
- Abstract
The severity of coronavirus disease 2019 (COVID-19) may be influenced by pre-existing immune responses against endemic coronaviruses, but conflicting data have been reported. We studied 148 patients who were hospitalised because of a confirmed diagnosis of COVID-19, classified mild in 58, moderate in 44, and severe in 46. The controls were 27 healthy subjects. At admission, blood samples were collected for the measurement of biomarkers of disease severity and levels of the IgG against the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and pre-existing coronaviruses OC43, HKU1, NL63 and 229E. Higher levels of IgG antibodies against the RBD of pre-existing coronavirus (with the highest significance for anti-HKU1 IgG, p = 0.01) were found in patients with mild disease, compared with those with moderate or severe disease. Multivariable logistic regression confirmed the association of high levels of antibodies to pre-existing coronavirus with mild disease and showed their associations with low levels of the complement activation marker SC5b-9 ( p range = 0.007-0.05). High levels of anti-NL63 antibodies were associated with low levels of the coagulation activation marker D-dimer ( p = 0.04), while high levels of IgG against 229E were associated with low levels of the endothelial activation marker von Willebrand factor ( p = 0.05). Anti-SARS-CoV-2-neutralising activity of plasma positively correlated with anti-SARS-CoV-2 IgG (r = 0.53, p = 0.04) and with anti-HKU1 IgG (r = 0.51, p = 0.05). In hospitalised patients with COVID-19, high levels of antibodies to pre-existing coronaviruses are associated with mild disease, suggesting that their measurement could be useful in predicting the severity of the disease.
- Published
- 2022
- Full Text
- View/download PDF
39. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.
- Author
-
Cugno M, Capone V, Griffini S, Grovetti E, Pintarelli G, Porcaro L, Clementi E, and Ardissino G
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized therapeutic use, Child, Child, Preschool, Complement System Proteins, Female, Humans, Infant, Kidney, Male, Middle Aged, Young Adult, Atypical Hemolytic Uremic Syndrome drug therapy, Atypical Hemolytic Uremic Syndrome genetics
- Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is characterized by platelet consumption, hemolysis, and renal injury. Eculizumab, a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule has not yet been clearly defined., Methods: Herein we report our experience with eculizumab maintenance treatment, in which the interval between subsequent doses was adjusted based on classical complement pathway (CCP) activity, targeted to < 30% for the prevention of relapses. Trough circulating levels of free eculizumab were determined by an immunoenzymatic method. Genetic and serologic characteristics of the patients were also assessed., Results: We report on 38 patients with aHUS with a median age of 25.0 years (range 0.5-60.0 years) treated with eculizumab. Once stable disease remission was obtained, the interval between eculizumab doses was extended based on target CCP activity. With this approach, presently, 22 patients regularly receive eculizumab infusion every 28 days and 16 receive it every 21. During a median observation period of 32.3 months (range 4.0-92.4 months) and a cumulative period of 1295 months, no patient relapsed. An inverse correlation between CCP activity and eculizumab circulating levels was present (r = - 0.690, p = 0.0001), with CCP activity being inhibited as long as free eculizumab was measurable in serum., Conclusions: In patients with aHUS on eculizumab maintenance treatment, complement activity measurement can be used as a proxy for circulating levels of the drug. Monitoring complement activity allows for safe tailoring of the frequency of eculizumab administration, thus avoiding excessive drug exposure while keeping the disease in remission., (© 2021. The Author(s) under exclusive licence to Italian Society of Nephrology.)
- Published
- 2022
- Full Text
- View/download PDF
40. Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored Eculizumab.
- Author
-
Ardissino G, Cresseri D, Tel F, Giussani A, Salardi S, Sgarbanti M, Strumbo B, Testa S, Capone V, Griffini S, Grovetti E, Cugno M, Belingheri M, Tamburello C, Rodrigues EM, Perrone M, Cardillo M, Corti G, Consonni D, Furian L, Tedeschi S, Messa P, and Beretta C
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Female, Humans, Plasmapheresis, Atypical Hemolytic Uremic Syndrome diagnosis, Atypical Hemolytic Uremic Syndrome drug therapy, Kidney Transplantation adverse effects
- Abstract
Rationale and Objective: Patients with atypical hemolytic uremic syndrome (aHUS) have long been considered ineligible for kidney transplantation (KTx) in several centers due to the high risk of disease recurrence, graft loss and life-threatening complications. The availability of Eculizumab (ECU) has now overcome this problem. However, the best approach towards timing, maintenance schedule, the possibility of discontinuation and patient monitoring has not yet been clearly established., Study Design: This is a single center case series presenting our experience with KTx in aHUS., Setting and Participants: This study included 26 patients (16 females) with a diagnosis of aHUS, who spent a median of 5.5 years on kidney replacement therapy before undergoing KTx. We compared the aHUS relapse rate in three groups of patients who underwent KTx: patients who received no prophylaxis, patients who underwent plasma exchange, those who received Eculizumab prophylaxis. Complement factor H-related disease was by far the most frequent etiology (n = 19 patients)., Results: Untreated patients and patients undergoing pre-KTx plasma exchange prophylaxis had a relapse rate of 0.81 (CI 0.30-1.76) and 3.1 (CI 0.64-9.16) events per 10 years cumulative observation, respectively, as opposed to 0 events among patients receiving Eculizumab prophylaxis. The time between Eculizumab doses was tailored based on classic complement pathway activity (target to < 30%). Using this strategy, 12 patients are currently receiving Eculizumab every 28 days, 5 every 24-25 days, and 3 every 21 days., Conclusion: Our experience supports the prophylactic use of Eculizumab in patients with a previous history of aHUS undergoing KTx, especially when complement dysregulation is well documented by molecular biology., (© 2021. Italian Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
41. Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.
- Author
-
Cugno M, Macor P, Giordano M, Manfredi M, Griffini S, Grovetti E, De Maso L, Mellone S, Valenti L, Prati D, Bonato S, Comi G, Artoni A, Meroni PL, and Peyvandi F
- Subjects
- Adult, Autoantibodies blood, COVID-19 Vaccines administration & dosage, ChAdOx1 nCoV-19, Female, Humans, Platelet Factor 4 blood, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Complement C2 genetics, Complement C2 metabolism, Complement Membrane Attack Complex genetics, Complement Membrane Attack Complex metabolism, Complement Pathway, Classical drug effects, Complement Pathway, Classical genetics, Complement Pathway, Mannose-Binding Lectin drug effects, Complement Pathway, Mannose-Binding Lectin genetics, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic chemically induced, Purpura, Thrombotic Thrombocytopenic genetics, SARS-CoV-2
- Abstract
Extremely rare reactions characterized by thrombosis and thrombocytopenia have been described in subjects that received ChAdOx1 nCoV-19 vaccination 5-16 days earlier. Although patients with vaccine-induced thrombotic thrombocytopenia (VITT) have high levels of antibodies to platelet factor 4 (PF4)-polyanion complexes, the exact mechanism of the development of thrombosis is still unknown. Here we reported serum studies as well as proteomics and genomics analyses demonstrating a massive complement activation potentially linked to the presence of anti-PF4 antibodies in a patient with severe VITT. At admission, complement activity of the classical and lectin pathways were absent (0% for both) with normal levels of the alternative pathway (73%) in association with elevated levels of the complement activation marker sC5b-9 (630 ng/mL [n.v. 139-462 ng/mL]) and anti-PF4 IgG (1.918 OD [n.v. 0.136-0.300 OD]). The immunoblotting analysis of C2 showed the complete disappearance of its normal band at 110 kDa. Intravenous immunoglobulin treatment allowed to recover complement activity of the classical pathway (91%) and lectin pathway (115%), to reduce levels of sC5b-9 (135 ng/mL) and anti-PF4 IgG (0.681 OD) and to normalize the C2 pattern at immunoblotting. Proteomics and genomics analyses in addition to serum studies showed that the absence of complement activity during VITT was not linked to alterations of the C2 gene but rather to a strong complement activation leading to C2 consumption. Our data in a single patient suggest monitoring complement parameters in other VITT patients considering also the possibility to target complement activation with specific drugs., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Relationship between thrombin generation parameters and prothrombin fragment 1 + 2 plasma levels.
- Author
-
Capecchi M, Scalambrino E, Griffini S, Grovetti E, Clerici M, Merati G, Chantarangkul V, Cugno M, Peyvandi F, and Tripodi A
- Subjects
- Adult, Blood Coagulation, Blood Coagulation Tests, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Peptide Fragments blood, Protein Precursors blood, Thrombin analysis, Peptide Fragments metabolism, Protein Precursors metabolism, Prothrombin metabolism, Thrombin metabolism
- Published
- 2021
- Full Text
- View/download PDF
43. Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595].
- Author
-
Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, and Cugno M
- Published
- 2021
- Full Text
- View/download PDF
44. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.
- Author
-
Cugno M, Berra S, Depetri F, Tedeschi S, Griffini S, Grovetti E, Caccia S, Cresseri D, Messa P, Testa S, Giglio F, Peyvandi F, and Ardissino G
- Subjects
- Adolescent, Adult, Atypical Hemolytic Uremic Syndrome diagnosis, Atypical Hemolytic Uremic Syndrome immunology, Case-Control Studies, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Young Adult, Atypical Hemolytic Uremic Syndrome blood, Autoantibodies blood, Complement Factor H immunology, Immunoglobulin M immunology
- Abstract
Background: Atypical hemolytic uremic syndrome (aHUS), a severe thrombotic microangiopathy, is often related to complement dysregulation, but the pathomechanisms remain unknown in at least 30% of patients. Researchers have described autoantibodies to complement factor H of the IgG class in 10% of patients with aHUS but have not reported anti-factor H autoantibodies of the IgM class., Methods: In 186 patients with thrombotic microangiopathy clinically presented as aHUS, we searched for anti-factor H autoantibodies of the IgM class and those of the IgG and IgA classes. We used immunochromatography to purify anti-factor H IgM autoantibodies and immunoenzymatic methods and a competition assay with mapping mAbs to characterize interaction with the target protein., Results: We detected anti-factor H autoantibodies of the IgM class in seven of 186 (3.8%) patients with thrombotic microangiopathy presented as aHUS. No association was observed between anti-factor H IgM and homozygous deletions involving CFHR3-CFHR1 . A significantly higher proportion of patients with bone marrow transplant-related thrombotic microangiopathy had anti-factor H IgM autoantibodies versus other patients with aHUS: three of 20 (15%) versus four of 166 (2.4%), respectively. The identified IgM autoantibodies recognize the SCR domain 19 of factor H molecule in all patients and interact with the factor H molecule, inhibiting its binding to C3b., Conclusions: Detectable autoantibodies to factor H of the IgM class may be present in patients with aHUS, and their frequency is six-fold higher in thrombotic microangiopathy forms associated with bone marrow transplant. The autoantibody interaction with factor H's active site may support an autoimmune mechanism in some cases previously considered to be of unknown origin., (Copyright © 2021 by the American Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
45. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
- Author
-
Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, and Cugno M
- Subjects
- Aged, Complement C5a genetics, Disease Progression, Female, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Hospitalization, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Risk, SARS-CoV-2 physiology, Viral Load, ABO Blood-Group System genetics, COVID-19 genetics, Chromosomes, Human, Pair 3 genetics, Complement Activation genetics, Genotype, Multigene Family genetics, White People
- Abstract
Background: Genetic variation at a multigene cluster at chromosome 3p21.31 and the ABO blood group have been associated with the risk of developing severe COVID-19, but the mechanism remains unclear. Complement activation has been associated with COVID-19 severity., Objective: The aim of this study was to examine whether chromosome 3p21.31 and the ABO variants are linked to the activation of the complement cascade in COVID-19 patients., Methods: We considered 72 unrelated European hospitalized patients with genetic data and evaluation of circulating C5a and soluble terminal complement complex C5b-9 (SC5b-9). Twenty-six (36.1%) patients carried the rs11385942 G>GA variant and 44 (66.1%) non-O blood group associated with increased risk of severe COVID-19., Results: C5a and SC5-b9 plasma levels were higher in rs11385949 GA carriers than in non-carriers (P = 0.041 and P = 0.012, respectively), while C5a levels were higher in non-O group than in O group patients (P = 0.019). The association between rs11385949 and SC5b-9 remained significant after adjustment for ABO and disease severity (P = 0.004) and further correction for C5a (P = 0.018). There was a direct relationship between upper airways viral load and SC5b-9 in carriers of the rs11385949 risk allele (P = 0.032), which was not observed in non-carriers., Conclusions: The rs11385949 G>GA variant, tagging the chromosome 3 gene cluster variation and predisposing to severe COVID-19, is associated with enhanced complement activation, both with C5a and terminal complement complex, while non-O blood group with C5a levels. These findings provide a link between genetic susceptibility to more severe COVID-19 and complement activation., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
- Author
-
Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Lonati P, Grossi C, Borghi MO, Novembrino C, Boscolo M, Uceda Renteria SC, Valenti L, Lamorte G, Manunta M, Prati D, Pesenti A, Blasi F, Costantino G, Gori A, Bandera A, Tedesco F, and Peyvandi F
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Male, Middle Aged, SARS-CoV-2, Biomarkers blood, COVID-19 blood, Complement Activation physiology, Endothelium, Vascular physiopathology
- Abstract
Background: Animal models and few clinical reports suggest the involvement of the complement system in the onset of severe manifestations of coronavirus disease-2019 (COVID-19). However, complement contribution to endotheliopathy and hypercoagulability has not been elucidated yet., Objective: To evaluate the association among complement activation, endothelial damage and disease severity or activity in COVID-19 patients., Methods: In this single-centre cohort study, 148 patients with COVID-19 of different severity were evaluated upon hospital admission and 30 days later. Markers of complement activation (SC5b-9 and C5a) and endothelial perturbation (von Willebrand factor [vWF], tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor-1 [PAI-1], soluble thrombomodulin [sTM], and soluble endothelial selectin [sE-selectin]) were measured in plasma., Results: The patients had high plasma levels of SC5b-9 and C5a (p = 0.0001 for both) and vWF, t-PA and PAI-1 (p = 0.0001 for all). Their SC5b-9 levels correlated with those of vWF (r = 0.517, p = 0.0001) and paralleled disease severity (severe vs mild p = 0.0001, severe vs moderate p = 0.026 and moderate vs mild p = 0.001). The levels of sE-selectin were significantly increased only in the patients with severe disease. After 30 days, plasma SC5b-9, C5a and vWF levels had significantly decreased (p = 0.0001 for all), and 43% of the evaluated patients had normal levels., Conclusions: Complement activation is boosted during the progression of COVID-19 and dampened during remission, thus indicating its role in the pathophysiology of the disease. The association between complement activation and the biomarkers of endothelial damage suggests that complement may contribute to tissue injury and could be the target of specific therapy., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
47. Complement activation in patients with COVID-19: A novel therapeutic target.
- Author
-
Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, and Peyvandi F
- Subjects
- Adult, Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Complement C5a analysis, Complement Membrane Attack Complex analysis, Coronavirus Infections immunology, Female, Humans, Male, Middle Aged, Pandemics, Pneumonia, Viral immunology, SARS-CoV-2, Complement Activation physiology, Coronavirus Infections blood, Pneumonia, Viral blood
- Published
- 2020
- Full Text
- View/download PDF
48. Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis.
- Author
-
Gualtierotti R, Ingegnoli F, Boscolo M, Griffini S, Grovetti E, and Cugno M
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, C-Reactive Protein drug effects, Female, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized pharmacology, Antirheumatic Agents pharmacology, Arthritis, Rheumatoid drug therapy, Factor XIII drug effects
- Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic systemic auto-immune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling disease activity and thrombotic risk. Factor XIII (FXIII), involved in thrombotic complications, has been reported to be reduced in RA patients during maintenance treatment with tocilizumab, but no data are available before and after the drug administration. Thus, we investigated the effects of tocilizumab on FXIII, thrombin generation and inflammation in patients with RA naïve for the drug., Methods: We studied 15 consecutive adult patients with RA at baseline and 4 weeks after the onset of parenteral administration of tocilizumab, measuring disease activity and plasma levels of C-reactive protein (CRP), FXIII, and prothrombin fragments F1+2 by immunoenzymatic methods. Fifteen healthy subjects, sex-and age-matched with patients, served as normal controls for laboratory measurements., Results: At baseline, patients with established RA had a median DAS28 of 4.8 (3.2-8.3) and, compared to healthy controls, had higher plasma levels of CRP (p < 0.0001), FXIII (p = 0.017) and F1+2 (p < 0.0001). Four weeks after starting treatment with tocilizumab, based on the EULAR response criteria, eight patients were classifiable as responders and seven as non-responders. In responders, we observed a statistically significant reduction not only of the values of DAS28 and CRP (p = 0.012 for both), ut also of plasma levels of FXIII (p = 0.05) and F1+2 (p = 0.025). In non-responders, all the studied parameters were unchanged., Conclusion: The decrease of FXIII and F1+2 levels after tocilizumab treatment observed only in those patients who responded to the drug indicates that the effect of tocilizumab on the prothrombotic state is linked to the control of inflammation and disease activity and not to a direct effect of the drug, thus contributing to the reduction of the cardiovascular risk.
- Published
- 2019
- Full Text
- View/download PDF
49. Italian version of the Assessment of Interprofessional Team Collaboration Scale II (I-AITCS II): a multiphase study of validity and reliability amongst healthcare providers.
- Author
-
Caruso R, Magon A, Dellafiore F, Griffini S, Milani L, Stievano A, and Orchard CA
- Subjects
- Adult, Cross-Sectional Studies, Female, Humans, Italy, Male, Psychometrics, Reproducibility of Results, Translations, Cooperative Behavior, Health Personnel, Interprofessional Relations, Self Report
- Abstract
Objective: To develop and validate an Italian version of the Assessment of Interprofessional Team Collaboration Scale II (I-AITCS II)., Methods: A multiphase validation study was conducted. The first phase was the AITCS-II translation from English into Italian to develop the first version of I-AITCS II for practitioners. The second phase was the study of I-AITCS II face and content validity, and the third phase was a cross-sectional data collection to provide evidence of construct validity using the psychometrics testing and the reliability assessment through the internal consistency study., Results: The agreement for the forward-translation among researchers was high. The face and content validity were satisfactory. The underlying constructs of I-AITCS II were partnership, cooperation and coordination. Internal consistency was good for both scale and domains level. There were significant differences related to partnership in the comparison between settings., Conclusions: I-AITCS II showed evidence of validity and reliability. It will be useful to gather data to address programs aimed to enhance interprofessional team collaboration within the Italian healthcare contexts, and it could be used for cross-national researches.
- Published
- 2018
- Full Text
- View/download PDF
50. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.
- Author
-
Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, and Cugno M
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Complement System Proteins analysis, Female, Humans, Infant, Male, Middle Aged, Retrospective Studies, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Atypical Hemolytic Uremic Syndrome drug therapy, Complement Inactivating Agents therapeutic use, Complement System Proteins drug effects, Drug Monitoring methods
- Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab (ECU), a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule is not yet clear., Methods: Here, we report our experience with ECU maintenance treatment and the interval between subsequent doses being extended based on global classical complement pathway (CCP) activity aimed at <30% for maintaining aHUS into remission., Results: We report on 38 patients with aHUS, 13 children, 21 female, with a median age of 25.0 years (range 0.5-60) at disease onset treated with ECU standard schedule for a median of 2.6 months (range 0.4-24.6). Once stable TMA remission was obtained, the interval between ECU doses was extended based on complement function, with a target CCP activity of <30%. With this approach, 22 patients regularly receive ECU infusion every 28 days and 16 every 21. During a median observation period on ECU, an extended interval of 26.9 months (range 0.8-80.9), with a cumulative observation period of 1,208 months, none of the patients relapsed., Conclusion: Monitoring complement activity allows a safe reduction in the frequency of ECU administration in aHUS while keeping the disease in remission.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.